ARE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alexandria Real Estate EquitiesNovember 28, 2025 9:35 AM EST | Source: Faruqi & Faruqi LLPFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Alexandria To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Alexandria between January 27, 2025 and October 27, 2025 and would like to discuss your legal rights ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant financial losses for investors [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Skye between November 4, 2024, and October 3, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [5]. - On October 6, 2025, Skye announced that its nimacimab did not achieve the primary endpoint of weight loss in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [6]. Group 3: Investor Communication - Faruqi & Faruqi encourages anyone with information regarding Skye's conduct, including whistleblowers and former employees, to contact the firm [8].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (ARE) due to alleged misrepresentations regarding its LIC property, which has led to significant stock losses for investors [1][2]. Summary by Sections Lawsuit Announcement - The lawsuit, Warren Hern v. Alexandria Real Estate Equities, Inc., was initiated in the United States District Court for the Central District of California for investors who acquired ARE securities between January 27, 2025, and October 27, 2025 [1]. Allegations of Misrepresentation - The complaint claims that ARE did not possess reliable information about its leasing spreads, development tenant pipeline, and expected occupancy growth for its life-science properties, particularly the LIC property [2]. - It is asserted that the value and growth potential of the LIC property had been declining for years, rendering the company's optimistic reports about its development pipeline and occupancy rates misleading [2]. Investor Support and Compensation - The firm Levi & Korsinsky encourages affected ARE shareholders to come forward before the January 26, 2026 deadline to seek justice and potential compensation for their losses [3]. - Investors do not need to serve as lead plaintiffs to share in any recovery from the lawsuit [3]. Firm's Track Record - Levi & Korsinsky has a history of securing substantial compensation for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant stock price declines [2][5][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Skye to contact them to discuss their legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false and misleading statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [5]. - On October 6, 2025, Skye announced that nimacimab did not achieve its primary endpoint in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [6]. Group 3: Investor Participation - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member, with no impact on their ability to share in any recovery [7]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Skye's conduct [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against WPP plc due to allegations of violations of federal securities laws related to misleading statements about the company's expected revenue for fiscal year 2025 [2][3]. Group 1: Allegations and Company Performance - The complaint alleges that WPP and its executives made false and misleading statements regarding the company's media division, claiming confidence in revitalization efforts while concealing the true challenges faced [2]. - WPP's trading update on July 9, 2025, indicated a deterioration in performance, attributing it to macroeconomic uncertainties and weaker new business than anticipated [3]. - Following the trading update, WPP's stock price dropped from $35.82 to $29.34, a decline of approximately 18.1% in one day [4]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased WPP securities between February 27, 2025, and July 8, 2025, are encouraged to discuss their legal rights and options, with a deadline of December 8, 2025, to seek the role of lead plaintiff in the class action [1][5]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [5]. - Faruqi & Faruqi, LLP is also seeking information from whistleblowers, former employees, and shareholders regarding WPP's conduct [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by December 2, 2025 [1][3]. Group 1: Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements regarding the company's medical cost trend assumptions and failed to disclose adverse facts affecting its financial outlook [3]. - Specific issues cited include a dislocation between premium rates and medical costs, reliance on low utilization of services, and the likelihood of substantial cuts to financial guidance for fiscal year 2025 [3]. Group 2: Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter results, reporting adjusted earnings of approximately $5.50 per share, which was below expectations, leading to a 10.2% cut in full-year earnings guidance from at least $24.50 to a range of $21.50 to $22.50 per share [4]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [4]. - On July 23, 2025, Molina further reduced its full-year earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year, and cutting guidance for full-year adjusted earnings to no less than $19.00 per diluted share, a 13.6% reduction [5]. - This led to a significant drop in Molina's stock price by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Stride, Inc. for alleged violations of federal securities laws, particularly regarding misleading statements about the company's products and services, which have led to significant investor losses [1][3]. Group 1: Allegations Against Stride - The complaint alleges that Stride and its executives made false and misleading statements about the company's offerings to educational institutions, while inflating enrollment numbers and cutting staff costs beyond legal limits [3]. - A report from Gallup-McKinley County Schools Board of Education accused Stride of fraud and deceptive practices, including retaining "ghost students" to secure state funding and ignoring compliance requirements [4]. Group 2: Stock Price Impact - Following the allegations, Stride's stock price dropped by $18.60, or 11.7%, closing at $139.76 per share on September 15, 2025, causing harm to investors [5]. - After Stride's announcement of limited enrollment growth and operational issues, the stock price fell as much as 51% during intraday trading on October 29, 2025, further injuring investors [6]. Group 3: Legal Proceedings - Investors who suffered losses during the specified period are encouraged to contact Faruqi & Faruqi to discuss their legal rights, with a deadline of January 12, 2026, to seek the role of lead plaintiff in the class action [1][7].

Core Points - Mobix Labs, Inc. has filed a verified complaint in the Delaware Court of Chancery against several defendants, including Tik Yang Tse, for fraud, intentional misrepresentation, and breach of investment obligations [1][2] - The lawsuit claims that ACE failed to fulfill its obligation to provide $30 million in funding related to Mobix's business merger in 2023, as stipulated in the subscription agreement [1][2] - Mobix is seeking over $250 million in damages and punitive damages, along with a specific performance of the $30 million equity investment commitment from ACE [2] Company Overview - Mobix Labs, Inc. is a rapidly developing semiconductor and defense technology company based in Irvine, California, focused on providing advanced wireless and wired connectivity solutions for next-generation communication systems [4] - The company's solutions support various high-reliability markets, including aerospace, defense, 5G, medical, and industrial sectors [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Stride, Inc. for alleged violations of federal securities laws, encouraging affected investors to contact them regarding their legal options [4][6]. Group 1: Allegations Against Stride, Inc. - The complaint alleges that Stride and its executives made false and misleading statements about the company's products and services, inflating enrollment numbers and cutting staff costs beyond statutory limits [6]. - A report from Gallup-McKinley County Schools Board of Education accused Stride of fraud and deceptive practices, including retaining "ghost students" to secure state funding [7]. - Following these allegations, Stride's stock price dropped significantly, falling $18.60 (11.7%) to close at $139.76 per share on September 15, 2025 [8]. Group 2: Financial Performance and Impact - On October 28, 2025, Stride reported first-quarter fiscal 2026 results, indicating a deliberate limitation on enrollment growth and issues with system implementation, leading to 10,000 to 15,000 fewer enrollments [9]. - The announcement of these challenges caused Stride's stock price to plummet by as much as 51% during intraday trading on October 29, 2025 [9]. Group 3: Legal Proceedings - Investors have until January 12, 2026, to seek the role of lead plaintiff in the federal securities class action against Stride [4]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [10].

Core Viewpoint - aTyr Pharma, Inc. is facing intensified financial and legal pressures following disappointing third-quarter results and ongoing securities class action litigation [1][4]. Financial Performance - aTyr reported a GAAP EPS loss of -$0.26 for Q3, missing analyst estimates by $0.08 [2]. - Revenues for the quarter were $190,000, indicating a reliance on the clinical pipeline rather than commercial sales [2]. Clinical Developments - Management plans to meet with the U.S. FDA in Q1 2026 to discuss the Phase 3 EFZO-FIT study results and the future of efzofitimod in treating pulmonary sarcoidosis [3]. - The EFZO-FIT study did not meet its primary endpoint, leading to a significant drop in stock price [5]. Legal Issues - aTyr is involved in securities class action litigation alleging that the company misled investors about efzofitimod's efficacy [4][6]. - The class period for the lawsuit has been expanded to include investors who acquired shares from November 7, 2024, to September 12, 2025 [6]. - The litigation claims that aTyr's positive statements about the drug concealed deficiencies in its performance and trial design [7]. Market Reaction - Following the announcement that the EFZO-FIT study did not meet its primary endpoint, aTyr's stock fell over 83% in one day, from $6.03 to $1.02 [5].